MX2021007345A - Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas. - Google Patents
Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas.Info
- Publication number
- MX2021007345A MX2021007345A MX2021007345A MX2021007345A MX2021007345A MX 2021007345 A MX2021007345 A MX 2021007345A MX 2021007345 A MX2021007345 A MX 2021007345A MX 2021007345 A MX2021007345 A MX 2021007345A MX 2021007345 A MX2021007345 A MX 2021007345A
- Authority
- MX
- Mexico
- Prior art keywords
- mitochondrial
- cscs
- therapeutic agent
- stem cells
- cancer stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Las células madre cancerosas (CSCs) pueden ser erradicadas a través de una estrategia terapéutica novedosa que implica, en algunas modalidades, antibióticos aprobados por la FDA y suplementos dietéticos. El presente planteamiento da por resultado de manera efectiva la erradicación sinérgica de CSCs a través de la inhibición de la biogénesis mitocondrial en CSCs durante el estrés oxidante mitocondrial inducido, sin inhibir las células normales. Las modalidades pueden incluir un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial grande, un agente terapéutico que inhibe la biogénesis mitocondrial y fija como objetivo el ribosoma mitocondrial pequeño y un agente terapéutico que se comporta como un pro-oxidante o induce el estrés oxidante mitocondrial. Las composiciones de acuerdo con el presente planteamiento inhibieron la propagación de CSC por ~90% en líneas de células MCF7 ER(+) durante estudios preliminares, con una reducción confirmada en el consumo de oxígeno mitocondrial y la producción de ATP. Algunas modalidades incluyen concentraciones sub-antimicrobianas de antibiótico, lo que minimiza en consecuencia los problemas de resistencia a antibióticos. En algunas modalidades, uno o más agentes terapéuticos se conjugan con una señal de fijación de objetivos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862780488P | 2018-12-17 | 2018-12-17 | |
US201962804411P | 2019-02-12 | 2019-02-12 | |
PCT/US2019/066541 WO2020131696A1 (en) | 2018-12-17 | 2019-12-16 | Triple combination therapies for targeting mitochondria and killing cancer stem cells |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007345A true MX2021007345A (es) | 2021-07-15 |
Family
ID=71102312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007345A MX2021007345A (es) | 2018-12-17 | 2019-12-16 | Terapias de combinacion triple para fijar como objetivo mitocondrias y aniquilar celulas madre cancerosas. |
Country Status (20)
Country | Link |
---|---|
US (1) | US20220040316A1 (es) |
EP (1) | EP3897658A4 (es) |
JP (1) | JP7487205B2 (es) |
KR (1) | KR20210104829A (es) |
CN (1) | CN113573715A (es) |
AU (1) | AU2019403048A1 (es) |
BR (1) | BR112021011963A2 (es) |
CA (1) | CA3123838A1 (es) |
CL (1) | CL2021001614A1 (es) |
CO (1) | CO2021008999A2 (es) |
CR (1) | CR20210350A (es) |
DO (1) | DOP2021000124A (es) |
EC (1) | ECSP21052747A (es) |
IL (1) | IL284056A (es) |
MX (1) | MX2021007345A (es) |
PE (1) | PE20211551A1 (es) |
PH (1) | PH12021551434A1 (es) |
SG (1) | SG11202106516VA (es) |
WO (1) | WO2020131696A1 (es) |
ZA (1) | ZA202104255B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4153563A4 (en) * | 2020-05-13 | 2024-06-19 | Lunella Biotech, Inc. | MYRISTOYL DERIVATIVES OF 9-AMINO-DOXYCYCLINE FOR TARGETING CANCER STEM CELLS AND PREVENTING METASTASIS |
WO2023200824A1 (en) * | 2022-04-13 | 2023-10-19 | The Wistar Institute Of Anatomy And Biology | Delivery system to target gram-negative bacteria |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK149776C (da) * | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
JP4573925B2 (ja) * | 1998-07-09 | 2010-11-04 | アベンティス・ファーマ・ソシエテ・アノニム | 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用 |
RU2223103C1 (ru) * | 2002-07-17 | 2004-02-10 | Открытое акционерное общество "Биосинтез" | Фармацевтическая композиция, обладающая антибактериальным действием |
CN1837229A (zh) * | 2005-08-05 | 2006-09-27 | 济南思创生物技术有限公司 | 克拉霉素衍生物及其制备方法和药物应用 |
WO2009038656A1 (en) * | 2007-09-17 | 2009-03-26 | Kosta Steliou | Mitochondria-targeting antioxidant therapeutics |
US20100173024A1 (en) * | 2008-12-01 | 2010-07-08 | LifeSpan Extension, LLC | Methods and compositions for altering health, wellbeing, and lifespan |
WO2013024467A2 (en) * | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
GB201217310D0 (en) * | 2012-09-27 | 2012-11-14 | C10 Pharma As | Compounds |
CN103536530A (zh) * | 2013-10-30 | 2014-01-29 | 王玉万 | 盐酸多西环素长效注射剂及制备方法 |
IL305316B2 (en) * | 2017-03-15 | 2024-09-01 | Lunella Biotech Inc | Mitoriboscines: Mitochondrial-Based Therapies Targeting Cancer Cells, Bacteria, and Pathogenic Yeasts |
CA3060510A1 (en) * | 2017-04-21 | 2018-10-25 | Lunella Biotech, Inc. | Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs) |
PE20200605A1 (es) * | 2017-05-19 | 2020-03-10 | Lunella Biotech Inc | Antimitoscinas: inhibidores especificos de la biogenesis mitocondrial para erradicar celulas madre cancerosas |
-
2019
- 2019-12-16 BR BR112021011963-9A patent/BR112021011963A2/pt unknown
- 2019-12-16 JP JP2021534980A patent/JP7487205B2/ja active Active
- 2019-12-16 EP EP19899234.9A patent/EP3897658A4/en active Pending
- 2019-12-16 WO PCT/US2019/066541 patent/WO2020131696A1/en active Search and Examination
- 2019-12-16 CA CA3123838A patent/CA3123838A1/en active Pending
- 2019-12-16 KR KR1020217022470A patent/KR20210104829A/ko unknown
- 2019-12-16 US US17/414,842 patent/US20220040316A1/en active Pending
- 2019-12-16 CR CR20210350A patent/CR20210350A/es unknown
- 2019-12-16 MX MX2021007345A patent/MX2021007345A/es unknown
- 2019-12-16 AU AU2019403048A patent/AU2019403048A1/en active Pending
- 2019-12-16 CN CN201980091489.9A patent/CN113573715A/zh active Pending
- 2019-12-16 SG SG11202106516VA patent/SG11202106516VA/en unknown
- 2019-12-16 PE PE2021000906A patent/PE20211551A1/es unknown
-
2021
- 2021-06-15 IL IL284056A patent/IL284056A/en unknown
- 2021-06-17 CL CL2021001614A patent/CL2021001614A1/es unknown
- 2021-06-17 DO DO2021000124A patent/DOP2021000124A/es unknown
- 2021-06-17 PH PH12021551434A patent/PH12021551434A1/en unknown
- 2021-06-21 ZA ZA2021/04255A patent/ZA202104255B/en unknown
- 2021-07-08 CO CONC2021/0008999A patent/CO2021008999A2/es unknown
- 2021-07-16 EC ECSENADI202152747A patent/ECSP21052747A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP7487205B2 (ja) | 2024-05-20 |
EP3897658A4 (en) | 2022-10-19 |
CL2021001614A1 (es) | 2022-01-14 |
PH12021551434A1 (en) | 2021-12-06 |
CA3123838A1 (en) | 2020-06-25 |
BR112021011963A2 (pt) | 2021-09-08 |
JP2022516414A (ja) | 2022-02-28 |
CO2021008999A2 (es) | 2021-07-30 |
DOP2021000124A (es) | 2021-08-15 |
PE20211551A1 (es) | 2021-08-16 |
ZA202104255B (en) | 2023-01-25 |
ECSP21052747A (es) | 2021-08-31 |
EP3897658A1 (en) | 2021-10-27 |
IL284056A (en) | 2021-08-31 |
US20220040316A1 (en) | 2022-02-10 |
SG11202106516VA (en) | 2021-07-29 |
CR20210350A (es) | 2021-09-27 |
AU2019403048A1 (en) | 2021-07-08 |
KR20210104829A (ko) | 2021-08-25 |
WO2020131696A1 (en) | 2020-06-25 |
CN113573715A (zh) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202202712B (en) | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells | |
PH12021551434A1 (en) | Triple combination therapies for targeting mitochondria and killing cancer stem cells | |
Saeidnia et al. | Antioxidants: friends or foe in prevention or treatment of cancer: the debate of the century | |
Esrefoglu | Experimental and clinical evidence of antioxidant therapy in acute pancreatitis | |
Sharma et al. | Effect of ethanolic and aqueous extracts of Bauhinia variegata Linn. on gentamicin-induced nephrotoxicity in rats | |
PH12020550685A1 (en) | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells | |
Murakami | Modulation of protein quality control systems by food phytochemicals | |
Li et al. | Melatonin sensitises shikonin-induced cancer cell death mediated by oxidative stress via inhibition of the SIRT3/SOD2-AKT pathway | |
MX2022009164A (es) | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. | |
BRPI0513466A (pt) | antivìrus natural e composição compreendendo o mesmo | |
WO2008012666A3 (en) | Treatment and prevention mucositis by anthocyanidin derivatives | |
Maatouk et al. | Heated naringin mitigate the genotoxicity effect of Mitomycin C in BALB/c mice through enhancing the antioxidant status | |
WO2018085816A1 (en) | Prooxidant cancer chemo-suppressors and chemo-protectors and methods of use related thereto | |
Waseem et al. | Mitochondria as the target for the modulatory effect of curcumin in oxaliplatin-induced toxicity in isolated rat liver mitochondria | |
TW200726460A (en) | Anti-fatigue composition | |
BR112015020178A2 (pt) | composição com propriedades de inflamação reduzidas para pele biológica e método de redução da inflamação do tecido biológico | |
WO2009100214A3 (en) | Induction of thyroid iodide-handling gene expression in human cancers | |
WO2016186349A3 (ko) | 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물 | |
Campbell et al. | Potential therapeutic agents | |
Woo et al. | Quercetin prevents necrotic cell death induced by co-exposure to benzo (a) pyrene and UVA radiation | |
AU2016413017B2 (en) | Bactericide composition | |
Verma et al. | Mechanism involved in fortification by berberine in CDDP-induced nephrotoxicity | |
BR112022014650A2 (pt) | Derivado de adamantila dissubstituído ou sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para suprimir o crescimento de câncer compreendendo o mesmo como ingrediente ativo | |
Abd-Rabou et al. | 5-fluorouracil synergized with raloxifene and cytosineβ-D-arabinofuranoside to combat colorectal cancers in vitro via controlling lipolysis | |
Munkhtsetseg et al. | Research on the acute toxicity of biologically active compounds derived from Sea buckthorn (Hippophae rhamnoides L.) flakes in vivo |